[go: up one dir, main page]

SG11201508113SA - Novel nanoparticle compositions - Google Patents

Novel nanoparticle compositions

Info

Publication number
SG11201508113SA
SG11201508113SA SG11201508113SA SG11201508113SA SG11201508113SA SG 11201508113S A SG11201508113S A SG 11201508113SA SG 11201508113S A SG11201508113S A SG 11201508113SA SG 11201508113S A SG11201508113S A SG 11201508113SA SG 11201508113S A SG11201508113S A SG 11201508113SA
Authority
SG
Singapore
Prior art keywords
nanoparticle compositions
novel nanoparticle
novel
compositions
nanoparticle
Prior art date
Application number
SG11201508113SA
Inventor
Howard Sosin
Michael Caplan
Tarek Fahmy
Original Assignee
Allertein Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allertein Therapeutics Llc filed Critical Allertein Therapeutics Llc
Publication of SG11201508113SA publication Critical patent/SG11201508113SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
SG11201508113SA 2013-04-03 2014-04-03 Novel nanoparticle compositions SG11201508113SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361808118P 2013-04-03 2013-04-03
PCT/US2014/032838 WO2014165679A1 (en) 2013-04-03 2014-04-03 Novel nanoparticle compositions

Publications (1)

Publication Number Publication Date
SG11201508113SA true SG11201508113SA (en) 2015-10-29

Family

ID=51659213

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201508113SA SG11201508113SA (en) 2013-04-03 2014-04-03 Novel nanoparticle compositions

Country Status (12)

Country Link
US (2) US9539217B2 (en)
EP (2) EP2981285B1 (en)
JP (2) JP2016516754A (en)
KR (1) KR102233251B1 (en)
CN (1) CN105188741A (en)
AU (1) AU2014248090B2 (en)
CA (1) CA2907915C (en)
IL (1) IL241807B (en)
MX (1) MX375502B (en)
SG (1) SG11201508113SA (en)
WO (1) WO2014165679A1 (en)
ZA (1) ZA201508106B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
KR102233251B1 (en) 2013-04-03 2021-03-26 엔-폴드 엘엘씨 Novel nanoparticle compositions
EP3160449B1 (en) 2014-06-24 2023-12-13 The Trustees of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
CA2916117C (en) * 2014-12-22 2023-02-28 Nishil Mohammed Pristine and surface functionalized cellulose nanocrystals (cncs) incorporated hydrogel beads and uses thereof
CN104689772B (en) * 2015-03-06 2017-08-11 天津大学 The method that polyphenol chemistry inspiration prepares high molecular microcapsule
WO2017112828A1 (en) 2015-12-22 2017-06-29 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
CN106913520A (en) * 2015-12-25 2017-07-04 上海医药集团股份有限公司 The particulate administration composition of Chinese mugwort Saperconazole
JP6977206B2 (en) * 2016-03-31 2021-12-08 富山県 Mucosal vaccine adjuvant that activates innate immunity
AU2017342558A1 (en) * 2016-10-14 2019-05-16 Icahn School Of Medicine At Mount Sinai Treatment of immunological disease using berberine nanoparticles
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K Cellulosic polymer nanoparticles and methods of forming them
CN109692327B (en) * 2017-10-23 2022-04-08 华中科技大学 Application of nano-particles for carrying melittin
EP3703667A4 (en) 2017-11-03 2021-08-04 The Trustees of Princeton University HYDROPHOBIC ION PAIRING AND FLASH NANOPRECIPITATION FOR THE FORMATION OF NANOCARIER FORMULATIONS WITH CONTROLLED RELEASE
KR102095355B1 (en) 2018-01-12 2020-03-31 주식회사 엠디헬스케어 Nanovesicles derived from Morganella bacteria and Use thereof
US12186436B2 (en) 2018-07-19 2025-01-07 The Trustees Of Princeton University Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
WO2020037151A1 (en) 2018-08-16 2020-02-20 Aimmune Therapeutics, Inc. Peanut oral immunotherapy with maintenance dose
JP7169837B2 (en) * 2018-10-03 2022-11-11 三菱鉛筆株式会社 Water-based ink composition for writing instruments
CN109776478B (en) * 2018-12-04 2022-10-14 福州大学 iso-Penicillixanthone A derived from Penicillium oxalicum and its application in cervical cancer
JP2022514645A (en) * 2018-12-20 2022-02-14 アイミューン セラピューティクス，インコーポレイテッド Dosing schedule for peanut oral immunotherapy
EP3902530A4 (en) * 2018-12-28 2023-01-25 Ramot at Tel-Aviv University Ltd. Polymeric nanovaccines and uses thereof
EP3911361A4 (en) * 2019-01-18 2022-10-12 University of Georgia Research Foundation, Inc. SALT NANOPARTICLES, RELATED COMPOSITIONS AND METHODS OF USE
US10398744B1 (en) 2019-02-08 2019-09-03 King Saud University Synthesis of mustard seed nanoparticles
CN113966229A (en) 2019-05-10 2022-01-21 爱沐疗法公司 Method for improving the quality of life of peanut allergic patients
EP4058059B1 (en) * 2019-11-13 2024-10-09 The Regents Of The University Of Michigan Nanoemulsion compositions for treating aeroallergen associated allergy and inflammation
BR112022009664A2 (en) * 2019-11-20 2022-08-16 Nestle Sa METHODS AND SYSTEMS FOR MANAGING THE DISTRIBUTION AND TREATMENT OF AN ORAL IMMUNOTHERAPY DRUG FOR FOOD ALLERGY
US20240197643A1 (en) * 2020-05-11 2024-06-20 University Of Southern California Oral delivery of nanoparticles for kidney disease
US20240197866A1 (en) * 2021-04-16 2024-06-20 Cour Pharmaceuticals Development Company Inc. Treatment of peanut allergy with tolerizing nanoparticles
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2024006870A2 (en) * 2022-06-29 2024-01-04 Massachusetts Institute Of Technology Structured nucleic acid templated architectures
KR20250080899A (en) * 2022-10-19 2025-06-05 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. Treatment of peanut allergy using tolerance nanoparticles
US12431000B2 (en) * 2024-02-27 2025-09-30 International Business Machines Corporation Detecting allergens using internet of things
WO2025212530A1 (en) 2024-04-01 2025-10-09 N-Fold Llc Nanoparticle manufacturing

Family Cites Families (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3977794A (en) 1974-07-15 1976-08-31 Coulter Electronics, Inc. Universal cell holder
DE2650306A1 (en) 1976-11-02 1978-05-03 Merck Patent Gmbh ANTIBACTERIAL DRESSING AND METHOD OF ITS MANUFACTURING
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
DE3260468D1 (en) 1981-01-09 1984-09-06 Sandoz Ag Novel cyclosporins
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5254562A (en) 1984-12-03 1993-10-19 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
AU98530S (en) 1985-06-20 1987-11-05 Novartis Ag Subdivided membrane controlled transdermal device
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5227467A (en) 1987-08-03 1993-07-13 Merck & Co., Inc. Immunosuppressive fluorinated cyclosporin analogs
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (en) 1988-11-03 1990-05-04 Tino Dalto SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5284826A (en) 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5225194A (en) * 1989-11-13 1993-07-06 Ldc Research Corporation Aqueous diafiltration process for preparing acellular vaccines, against selected bacterial diseases
US5208228A (en) 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
US5122511A (en) 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
PT98990A (en) 1990-09-19 1992-08-31 American Home Prod PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID ESTERS OF RAPAMICIN
US5143918A (en) 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5565560A (en) 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5262533A (en) 1991-05-13 1993-11-16 Merck & Co., Inc. Amino O-aryl macrolides having immunosuppressive activity
US5162334A (en) 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5250678A (en) 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5120725A (en) 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5169851A (en) 1991-08-07 1992-12-08 American Home Products Corporation Rapamycin analog as immunosuppressants and antifungals
US5202332A (en) 1991-08-07 1993-04-13 American Home Products Corporation Rapamycin analog as immunosuppressant
US5189042A (en) 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
US5208241A (en) 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
SE9102652D0 (en) 1991-09-13 1991-09-13 Kabi Pharmacia Ab INJECTION NEEDLE ARRANGEMENT
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US6911220B1 (en) 1992-02-19 2005-06-28 The General Hospital Corporation Allogeneic and xenogeneic transplantation
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5284840A (en) 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5558869A (en) 1992-12-30 1996-09-24 University Of Arkansas Major peanut allergen ara h II
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
WO1995003356A1 (en) 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
IT1261849B (en) 1993-09-02 1996-06-03 Avantgarde Spa MEDICAL DEVICE FOR THE ADMINISTRATION OF ACTIVE INGREDIENTS OR VERY LOW DOSAGE DRUGS, IN PARTICULAR HOMEOPATHIC DRUGS.
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5693648A (en) 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
DE69630514D1 (en) 1995-01-05 2003-12-04 Univ Michigan SURFACE-MODIFIED NANOPARTICLES AND METHOD FOR THEIR PRODUCTION AND USE
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US6126936A (en) 1995-03-10 2000-10-03 Biohybrid Technologies Llc Microcapsules and composite microreactors for immunoisolation of cells
KR100201352B1 (en) 1995-03-16 1999-06-15 성재갑 Single injection vaccine formulation
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
PT752245E (en) 1995-07-05 2002-09-30 Europ Economic Community BIOCOMPATIBLE AND BIODEGRADABLE NANOPARTICLES FOR THE ABSORPTION AND ADMINISTRATION OF PROTEINACEAL DRUGS
DE19537012A1 (en) 1995-10-04 1997-04-10 Dietl Hans Pharmaceutical preparation containing cyclosporin (s) for oral administration and process for its preparation
US20030202980A1 (en) 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US6835824B1 (en) 1995-12-29 2004-12-28 University Of Arkansas Peanut allergens and methods
EP0873135B1 (en) 1995-12-29 2009-07-22 The University of Arkansas Peanut allergens and methods
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
WO1997041863A1 (en) 1996-05-09 1997-11-13 The General Hospital Corporation Mixed chimerism and tolerance
US5739432A (en) 1996-05-30 1998-04-14 The Regents Of The University Of California Ultrasonic characterization of single drops of liquids
US5709797A (en) 1996-06-05 1998-01-20 Poli Industria Chimica S.P.A. Method of isolating cyclosporins
US5774209A (en) 1996-10-08 1998-06-30 Spectronic Instruments, Inc. Transmittance cell for spectrophotometer
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP2172216A3 (en) 1997-03-10 2010-11-24 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP0980269A1 (en) * 1997-04-30 2000-02-23 Guilford Pharmaceuticals Inc. Biodegradable compositions comprising poly(cycloaliphatic phosphoester) compounds, articles, and methods for using the same
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
DE69840586D1 (en) 1997-10-08 2009-04-02 Isotechnika Inc Deuterated cyclosporin analogs and their use as immunomodulating agents
IT1298087B1 (en) 1998-01-08 1999-12-20 Fiderm S R L DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS
JP2002509117A (en) 1998-01-16 2002-03-26 ザ・ジョーンズ・ホプキンス・ユニバーシティ Oral administration of nucleic acid vaccine by granular complex
EP1051626B1 (en) 1998-01-30 2009-03-18 Allertein Therapeutics, LLC Prognostic allergy or inflammation test
US7879977B2 (en) 1998-01-31 2011-02-01 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
DE69940805D1 (en) 1998-01-31 2009-06-10 Sinai School Medicine METHOD AND REAGENTS FOR REDUCING THE CLINICAL REACTION TO ALLERGY
US5965154A (en) 1998-03-17 1999-10-12 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
SE9801288D0 (en) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and method of production
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
IL140899A0 (en) 1998-07-17 2002-02-10 Skyepharma Inc Lipid/polymer containing pharmaceutical compositions and processes for the preparation thereof
FR2785812B1 (en) 1998-11-16 2002-11-29 Commissariat Energie Atomique BIOACTIVE PROSTHESES, IN PARTICULAR WITH IMMUNOSUPPRESSIVE PROPERTIES, ANTISTENOSIS AND ANTITHROMBOSIS, AND THEIR MANUFACTURE
US6551990B2 (en) 1998-12-07 2003-04-22 University Of Washington Methods of inhibiting ectopic calcification
AU2196500A (en) 1998-12-18 2000-07-03 Michael Caplan Methods and compositions for decreasing allergic reactions to surface allergens
CA2357413A1 (en) 1998-12-22 2000-06-29 Panacea Pharmaceuticals, Llc Sensitizing agents for the treatment of skin lesions
US20020009452A1 (en) 1999-02-10 2002-01-24 Michael Caplan Method for altering undesirable immune responses to polypeptides
WO2000054803A2 (en) 1999-03-16 2000-09-21 Panacea Pharmaceuticals, Llc Immunostimulatory nucleic acids and antigens
US20020090381A1 (en) 1999-04-09 2002-07-11 H. Kim Bottomly System for controlling immune system response to antigen
EP1210579B1 (en) 1999-08-20 2008-06-04 NanoDrop Technologies, LLC Liquid photometer using surface tension to contain sample
AU4139801A (en) 1999-12-06 2001-06-12 Board Of Trustees Of The University Of Arkansas, The Controlled delivery of antigens
ATE319475T1 (en) 2000-04-06 2006-03-15 Seer Pharmaceuticals Llc MICROBIAL ACTIVE DELIVERY SYSTEM
US8246945B2 (en) 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US20040142475A1 (en) 2000-06-02 2004-07-22 Barman Shikha P. Delivery systems for bioactive agents
WO2002030456A1 (en) 2000-10-12 2002-04-18 The University Of Tennessee Research Corporation Targeting drug/gene carriers to irradiated tissue
US6676963B1 (en) 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US6544543B1 (en) 2000-12-27 2003-04-08 Advanced Cardiovascular Systems, Inc. Periodic constriction of vessels to treat ischemic tissue
US6809826B2 (en) 2001-02-20 2004-10-26 Charles William Robertson Liquid photometer using surface tension to contain sample
EP1389071A2 (en) 2001-02-26 2004-02-18 Sabina Glozman Systems devices and methods for intrabody targeted delivery and reloading of therapeutic agents
WO2002076441A1 (en) 2001-03-21 2002-10-03 University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles
US20030153044A1 (en) 2001-05-14 2003-08-14 Monika Liljedahl Tissues or organs for use in xenotransplantation
US20030003591A1 (en) 2001-07-02 2003-01-02 Ortho-Clinical Diagnostics, Inc. Reaction vessel
US7081489B2 (en) 2001-08-09 2006-07-25 Florida State University Research Foundation Polymeric encapsulation of nanoparticles
US20040023897A1 (en) 2001-11-13 2004-02-05 Caplan Michael J. Methods for preventing or treating disease mediated by toxin-secreting bacteria
WO2003048298A2 (en) 2001-12-05 2003-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof
US20030235619A1 (en) 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
US20040038303A1 (en) 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US7285289B2 (en) 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
EP1583473A2 (en) 2003-01-16 2005-10-12 St. Johns University New York Nanoparticle based stabilization of ir fluorescent dyes
JP4509999B2 (en) 2003-02-17 2010-07-21 ブルクハルト，ペーター Peptide nanoparticles as pharmaceutical delivery and antigen presentation systems
RU2006110526A (en) 2003-09-02 2007-10-10 Юниверсити Оф Норт Каролина Эт Чепел Хилл (Us) Biodegradable Polymer Ligand Conjugates and Their Use for Isolation of Cell Subpopulations and for Cryopreservation, Culopreservation, Cultivation and Cell Transplantation
ES2246695B1 (en) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. STIMULATING COMPOSITION OF THE IMMUNE RESPONSE THAT INCLUDES NANOPARTICLES BASED ON A COPYLIMER OF METHYL VINYL ETER AND MALEIC ANHYDRIDE.
US20080260851A1 (en) 2004-05-13 2008-10-23 The Trustees Of Columbia University In The City Of New York Polymeric Nanoparticles and Nanogels for Extraction and Release of Compounds
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US9079765B2 (en) 2004-10-01 2015-07-14 Midatech Ltd. Nanoparticles comprising antigens and adjuvants, and immunogenic structures
US7375815B2 (en) 2004-10-12 2008-05-20 Agilent Technologies, Inc. Optical devices, systems and method for producing a collimated light path
US20060087650A1 (en) 2004-10-21 2006-04-27 Shen Thomas Y Cuvette holder for spectrophotometers
US20060109468A1 (en) 2004-11-24 2006-05-25 Evans Richard W Devices, methods, and systems for measuring an optical property of a sample
BRPI0607162B1 (en) 2005-02-11 2018-08-14 Nanodrop Technologies, Llc. APPLIANCE FOR MEASURING FLUORESCENCE OF A SAMPLE FLUORESCENT AND METHOD FOR MEASURING FLUORESCENCE OF A SAMPLE
EP1716847B1 (en) 2005-04-28 2008-01-02 Nipro Corporation Bioabsorbable pharmaceutical formulation comprising a PLGA copolymer
US8252846B2 (en) 2005-05-10 2012-08-28 Emory University Strategies for delivery of active agents using micelles and particles
US20070092575A1 (en) 2005-05-10 2007-04-26 Naomi Balaban Compositions for administering RNAIII-inhibiting peptides
US20070026126A1 (en) 2005-08-01 2007-02-01 Bryan Hitchcock Sterol fortified beverages
JP5484732B2 (en) 2005-12-14 2014-05-07 サイトス バイオテクノロジー アーゲー Immunostimulatory nucleic acid package particles for the treatment of hypersensitivity
US8021689B2 (en) 2006-02-21 2011-09-20 Ecole Polytechnique Federale de Lausanne (“EPFL”) Nanoparticles for immunotherapy
US9188594B2 (en) 2006-12-06 2015-11-17 Yale University Nanoelectronic-enzyme linked immunosorbent assay system and method
WO2008115641A2 (en) 2007-02-15 2008-09-25 Yale University Modular nanoparticles for adaptable vaccines
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
AU2008217189B2 (en) * 2007-02-22 2013-06-13 Baxalta GmbH Method of purification of hydrophobic proteins
WO2008109347A2 (en) 2007-03-02 2008-09-12 Yale University Methods for ex vivo administration of drugs to grafts using polymeric nanoparticles
WO2009038591A1 (en) 2007-09-17 2009-03-26 Yale University Bile salt colloids and methods of making and using thereof
JP5410434B2 (en) * 2007-09-28 2014-02-05 バインド セラピューティックス インコーポレイテッド Targeting cancer cells with nanoparticles
CA2917512C (en) * 2007-10-12 2025-08-05 President And Fellows Of Harvard College Vaccine nanotechnology
GB0721081D0 (en) 2007-10-26 2007-12-05 Metcalfe Susan M Immuno-modulatory composition
US8629098B2 (en) 2008-01-15 2014-01-14 Yale University Compositions and methods for adoptive and active immunotherapy
US9737593B2 (en) 2008-03-19 2017-08-22 Yale University Carbon nanotube compositions and methods of use thereof
EP2303236A4 (en) 2008-07-01 2012-09-26 Univ Emory SYNERGISTIC INDUCTION OF HUMORAL AND CELLULAR IMMUNITY BY MEANS OF COMBINATORY ACTIVATION OF GREAT LIKE RECEPTORS
US20100031262A1 (en) 2008-07-31 2010-02-04 Baird-Gent Jill M Program Schedule Sub-Project Network and Calendar Merge
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US9283184B2 (en) 2008-11-24 2016-03-15 Massachusetts Institute Of Technology Methods and compositions for localized agent delivery
SG173041A1 (en) 2009-01-20 2011-08-29 Univ Northwestern Compositions and methods for induction of antigen-specific tolerance
US8822065B2 (en) 2009-03-11 2014-09-02 Samsung Sdi Co., Ltd. Rechargeable battery with current collector plate
WO2011014866A1 (en) 2009-07-31 2011-02-03 Mount Sinai School Of Medicine Of New York University Materials and methods for diagnosing and treating shellfish allergy
EP2478373B1 (en) 2009-09-14 2019-01-09 Icahn School of Medicine at Mount Sinai Methods for characterizing antibody binding affinity and epitope diversity in food allergy
US8727965B2 (en) 2010-03-05 2014-05-20 Tissue Genesis, Inc. Methods and compositions to support tissue integration and inosculation of transplanted tissue and transplanted engineered penile tissue with adipose stromal cells
WO2011150235A1 (en) 2010-05-27 2011-12-01 Allertein Therapeutics, Llc Methods and reagents for treating autoimmune disorders and/or graft rejection
EP2593098A4 (en) 2010-07-16 2014-02-05 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY
JP5909745B2 (en) 2010-11-12 2016-04-27 クール ファーマシューティカルズ ディベロップメント カンパニー Drugs for inflammatory diseases as well as drugs for viral or bacterial infections
MX373641B (en) 2011-04-29 2020-05-04 Selecta Biosciences Inc SYNTHETIC TOLEROGENETIC NANOCARRIERS FOR ALLERGY THERAPY.
WO2012167261A2 (en) 2011-06-03 2012-12-06 Yale University Compositions and methods for treating and preventing neointimal stenosis
US9326951B2 (en) 2011-06-28 2016-05-03 Yale University Cell-free tissue engineered vascular grafts
PL2836234T3 (en) 2012-04-12 2020-02-28 Yale University Vehicles for controlled delivery of different pharmaceutical agents
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
US20150150996A1 (en) 2012-06-06 2015-06-04 Northwestern University Compositions and methods for antigen-specific tolerance
KR20220166879A (en) 2012-06-21 2022-12-19 노쓰웨스턴유니버시티 Peptide conjugated particles
EP2887954B1 (en) 2012-08-23 2020-05-06 Susan Marie Metcalfe Neurotherapeutic nanoparticle compositions
KR20250076678A (en) 2013-03-13 2025-05-29 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. Immune-modifying particles for the treatment of inflammation
KR102233251B1 (en) 2013-04-03 2021-03-26 엔-폴드 엘엘씨 Novel nanoparticle compositions
HRP20192270T4 (en) 2013-08-13 2024-03-01 Northwestern University CONJUGATED PEPTIDE PARTICLES
US20160228521A1 (en) 2013-09-16 2016-08-11 Allertein Therapeutics, Llc Managing immune responses in transplantation
US9884026B2 (en) 2013-11-01 2018-02-06 Yale University Modular particles for immunotherapy
WO2015175597A1 (en) 2014-05-13 2015-11-19 Yale University Compositions for nanoconfinement induced contrast enhancement and methods of making and using thereof
WO2016057909A1 (en) 2014-10-10 2016-04-14 Cour Pharmaceuticals Development Company Immune-modifying particles for the treatment of ebola virus
US20160346382A1 (en) 2015-05-27 2016-12-01 Northwestern University Carbohydrate-modified particles and particulate formulations for modulating an immune response
WO2017075053A1 (en) 2015-10-26 2017-05-04 Cour Pharmaceuticals Development Company Inc. Immune-modifying particles for the treatment of malaria
AU2016379413B2 (en) 2015-12-23 2024-04-04 Cour Pharmaceuticals Development Company Inc. Covalent polymer-antigen conjugated particles
CA3009799A1 (en) 2016-01-04 2017-07-13 Cour Pharmaceuticals Development Company Inc. Particles encapsulating fusion proteins containing linked epitopes
JP2019504895A (en) 2016-02-09 2019-02-21 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド TIMP encapsulating cedar pollen epitope (tissue metalloprotease inhibitor)
EP3416624B8 (en) 2016-02-18 2023-08-23 Cour Pharmaceuticals Development Company Inc. Process for the preparation of tolerizing immune-modulating particles

Also Published As

Publication number Publication date
ZA201508106B (en) 2018-12-19
MX2015013894A (en) 2015-12-11
EP2981285A4 (en) 2016-11-09
US20170071867A1 (en) 2017-03-16
US9999600B2 (en) 2018-06-19
AU2014248090B2 (en) 2018-08-02
WO2014165679A1 (en) 2014-10-09
IL241807B (en) 2019-08-29
CA2907915C (en) 2023-03-07
EP3760223A1 (en) 2021-01-06
AU2014248090A1 (en) 2015-11-12
CA2907915A1 (en) 2014-10-09
JP2019073525A (en) 2019-05-16
KR20150138857A (en) 2015-12-10
HK1221165A1 (en) 2017-05-26
MX375502B (en) 2025-03-04
US20160113881A1 (en) 2016-04-28
EP2981285A1 (en) 2016-02-10
JP2016516754A (en) 2016-06-09
KR102233251B1 (en) 2021-03-26
EP2981285B1 (en) 2020-06-03
CN105188741A (en) 2015-12-23
BR112015022506A2 (en) 2017-10-24
US9539217B2 (en) 2017-01-10
JP6756810B2 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
ZA201508106B (en) Novel nanoparticle compositions
GB201304662D0 (en) Compositions
GB201319525D0 (en) Composition
GB201302427D0 (en) Nanoparticle delivery compositions
GB201608461D0 (en) Compositions
EP3006525A4 (en) Asphalt-urethane composition
GB201318489D0 (en) Composition
GB201319540D0 (en) Composition
GB201320919D0 (en) Composition
GB201317388D0 (en) Composition
GB201317105D0 (en) Novel Composition
GB201320303D0 (en) Composition
GB201319538D0 (en) Composition
GB201306984D0 (en) Composition
GB201317196D0 (en) Composition
GB201307622D0 (en) Composition
ZA201505650B (en) New compositions
GB201320962D0 (en) Compositions
GB201316463D0 (en) Novel compositions
GB201319923D0 (en) Novel composition
GB201320504D0 (en) Composition
GB201310513D0 (en) Novel composition
GB201308502D0 (en) Composition
GB201301774D0 (en) Composition
GB201318394D0 (en) Composition